Myopia Control: a Comparison Study Between Atropine and MiSight

Part of paid clinical trials in Chicago, Illinois.

Sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Study ID
NCT05815784
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Myopia

Eligibility Criteria

Sex
ALL
Age
5 Years - 12 Years
Healthy Volunteers
Not accepted

Interventions

  • Atropine — DRUG
    0.05% atropine. One drop per eye per day for 2 years.
  • MiSight contact lenses — DEVICE
    Daily wear for 2 years.

Study Details

This research project aims to provide additional knowledge of pharmacological and optical methods of myopia control and to gain a better understanding of the biometry of the pediatric eye, which contributes to the onset and progression of myopia. As a result, this study will improving our best practices for myopia control in pediatric patients.

Key Dates

Start date
May 2, 2023
Status verified
Nov 2024
Primary completion
Mar 13, 2026
Completion
Mar 13, 2026

Study Design

Enrollment
348 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • No Intervention: Observation
    No treatment.
  • Other: Atropine
    0.05% atropine. One drop per eye per day for 2 years.
  • Other: MiSight contact lenses
    MiSight contact lenses. Daily wear for 2 years.

Primary Outcome Measure

axial length [ Time Frame: 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Ann & Robert H. Lurie Children's Hospital of ChicagoChicagoIllinois60611
Chia-Ching Wu, MS
Hanta Ralay Ranaivo, PhD

Find similar trials in Chicago, IL

By research site
Ann & Robert H. Lurie Children's Hospital of Chicago· Chicago, IL

Related Studies